Structured intelligence on corporate strategy, market moves, and industry signals.
Each entry is a briefing, not a headline: event summary, strategic context, and what to watch next.
A Company Pulse is our reading of what a company says in its own press release, with the questions we would want answered. It is not verified reporting and it is not an endorsement. Pulses are made from press releases we collect from several sources, including Wire. Nobody can pay for a Pulse.
Xenon Pharmaceuticals remains on track to submit its NDA for azetukalner in focal onset seizures (FOS) by Q3 2026, following a successful pre-NDA meeting with the FDA.
Barzolvolimab Phase 3 trials in chronic spontaneous urticaria completed enrollment six months ahead of schedule, with topline data expected September/October 2026.
IN8bio reported median overall survival exceeding 19.5 months in glioblastoma patients treated with DeltEx™ DRI, compared to 13.2 months for standard-of-care.
